CODEX DNA INC (DNAY)

Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful...

Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 --...

Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today...

Telesis Bio et Cellibre annoncent une collaboration pour optimiser le développement du futur instrument BioXp® DBC

Cet accord permettra aux chercheurs de rationaliser le développement de la production à la demande et automatisée de l'ARN guide CRISPR-Cas9...

Telesis Bio und Cellibre kündigen Zusammenarbeit an, um die Entwicklung des künftigen BioXp® DBC-Instruments zu optimieren

Vereinbarung wird es Forschern ermöglichen, die Entwicklung der On-Demand- und automatisierten Produktion von CRISPR-Cas9-Leit-RNA zu rationalisieren...

Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument

Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNA...

Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument

Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNA

Codex DNA annonce son intention de changer son nom d'entreprise en Telesis Bio

Ce nouveau nom reflète l'expansion de ses capacités et solutions...

Codex DNA kündigt Plan zur Umfirmierung in Telesis Bio an

Der neue Name spiegelt die Erweiterung der Fähigkeiten und Lösungen wider...

Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

Novel name reflects expansion of capabilities and solutions

Codex DNA Expands Application of Proprietary Error Correction Technology

New BioXp® Error Corrected Libraries have two-fold increase in sequence fidelity...

Codex DNA étend l'application de la technologie exclusive de correction des erreurs

Les nouvelles bibliothèques avec correction des erreurs BioXp® ont multiplié par deux la fidélité séquentielle...

Codex DNA weitet Anwendung der firmeneigenen Fehlerkorrekturtechnologie aus

Neue fehlerkorrigierte BioXp®-Bibliotheken mit zweifach erhöhter Sequenztreue...

Codex DNA Expands Application of Proprietary Error Correction Technology

New BioXp® Error Corrected Libraries have two-fold increase in sequence fidelity

Codex DNA présente sa prochaine génération de postes de travail de biologie synthétique automatisée lors de la conférence World of Technology & Science à Utrecht, aux Pays-Bas

BioXp™ 9600, un instrument de paillasse à haut débit entièrement automatisé pour les flux de travail de biologie synthétique, a été nommé pour le...

Codex DNA präsentiert automatisierte synthetische Biologie-Workstation der nächsten Generation auf der World of Technology & Science in Utrecht, Niederlande

BioXp™ 9600-System – ein vollautomatisches Tischgerät mit hohem Durchsatz für Arbeitsabläufe in der synthetischen Biologie – nominiert für den renommierten...

Codex DNA presenteert Next Generation Automated Synthetic Biology Workstation op World of Technology & Science in Utrecht, Nederland

BioXp™ 9600-systeem – een volledig geautomatiseerd, tafelmodel-instrument met hoge doorvoer voor synthetisch-biologische werkstromen – genomineerd voor de...

Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands

BioXp™ 9600 system – a fully automated, high-throughput benchtop instrument for synthetic biology workflows – nominated for prestigious World of Laboratory...

Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation

BioXp™ 9600 system – a fully automated, high-throughput benchtop instrument for synthetic biology workflows – empowers scientists to accelerate discovery...

Codex DNA Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported...

Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?

The FDA's advisors recently backed Pfizer's Covid shot for young children.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

We're starting off Thursday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on!

Codex DNA vs. Binance Coin: Price Relationship Crosses Threshold

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning! It's time to start off another busy day of trading with a look at the biggest pre-market stock movers for Wednesday!